Institute of Human Virology at the University of Maryland School of Medicine Research Suggests that Bacterial Infections May Contribute Far More to Cancers Than Previously Thought
Baltimore, Maryland, USA, December 4, 2018: The Institute of Human Virology (IHV) at the University of Maryland School of Medicine, a Global Virus Network Center of Excellence, announced today the discovery that DnaK, a protein of the bacterium mycoplasma, interferes with the mycoplasma-infected cell’s ability to respond to and repair DNA damage, a known origin of cancer.
Little or no mycoplasma DnaK DNA sequences were found associated with the tumor, which was fully developed, suggesting a hit-and-run or hide mechanism of transformation, indicating that the damage is done early but the protein may not be needed once the cancer cells are formed.
The study was published yesterday in the Proceedings of the National Academy of Sciences and suggests that bacterial infections may contribute to far more cancers than previously thought. The announcement was made by Robert Gallo, MD, The Homer & Martha Gudelsky Distinguished Professor in Medicine, Co-Founder and Director, Institute of Human Virology, University of Maryland School of Medicine and Co-Founder and Scientific Director, Global Virus Network and Davide Zella, PhD, Assistant Professor of Biochemistry and Molecular Biology, Institute of Human Virology, University of Maryland School of Medicine. Drs. Gallo and Zella collaborated with Hervé Tettelin, PhD, Associate Professor of Microbiology and Immunology, Institute for Genome Sciences, University of Maryland School of Medicine.
“Currently, approximately 20% of cancers are thought to be caused by infection, most are known to be due to viruses,” said Dr. Gallo. “Mycoplasmas are a family of bacteria that are associated with cancers, especially in people with HIV. Our work provides an explanation for how a bacterial infection can trigger a series of events that lead to cancer. Of particular importance, the infection did not need to persist and the protein did not need to be continuously present in all cancer cells. The study also provides a mechanism for how some bacterial infections can interfere with specific cancer drugs.”
Researchers utilized immune-compromised mice as a model for analyzing the effect of mycoplasma infection on the development of lymphoma. They compared how quickly non- infected immune-compromised mice developed lymphoma compared to mycoplasma-infected immune-compromised mice. The mice were infected with a strain of mycoplasma from an HIV patient. The researchers found that mycoplasma infection caused the mice to develop lymphoma earlier in life than noninfected immune-compromised mice and that some, but not all, of the cancer cells had bacterial DNA. Finding only a small amount of bacterial DNA in the cancer cells suggested that the infection did not have to persist to trigger cancer.
“We focused on a protein called DnaK, which is part of a family of proteins that function as a ‘chaperone’ for other proteins protecting them from damage or helping them to fold,” said Dr. Zella. “However, in this case, DnaK reduces the activity of important cellular proteins involved in DNA repair and anti-cancer-activities, such as p53. Thus, cells infected with mycoplasma would not be able to properly repair damaged DNA, thus, potentially increasing the risk for cancer development.”
The scientists noted that the bacteria can release DnaK and the DnaK enters nearby uninfected cells. The study also demonstrates that by reducing p53, DnaK can also reduce the efficacy of anti-cancer drugs. Thus, mycoplasma infection could not only trigger events leading to the accumulation of DNA damage and oncogenesis in infected cells, but also trigger cancer-causing events in nearby uninfected cells that took up DnaK released from infected neighboring cells.
“We analyzed the amino acid sequences of DnaK from many bacteria and found that the DnaK proteins from bacteria associated with cancer grouped together were different DnaK sequences from bacteria that are not associated with cancer,” said Dr. Tettelin. “This raises the possibility that other bacteria have the same cancer-promoting ability.”
According to Dr. Gallo, “This hit-and-run, or hide, mechanism mediated by a protein common to many cancer-associated bacteria changes how we need to think about infection and at least some cancers. Furthermore, this provides a basis for understanding how infection can influence the effectiveness of some cancer treatments.”
“This is fascinating science with important implications,” said UMSOM Dean E. Albert Reece, MD, PhD, MBA, who is also the Executive Vice President for Medical Affairs, University of Maryland, and the John Z. and Akiko K. Bowers Distinguished Professor. “We are pleased to see a cross-collaboration between two disciplines here at the University of Maryland School of Medicine. Our Institute of Human Virology’s basic science laboratory research was aided by the School’s Institute of Genome Sciences’ sequencing expertise, bringing the research to full fruition.”
This research was partially funded by the Maryland Cigarette Restitution Fund (CRF) Program. Morgan State University also participated in this study.
About the Institute of Human Virology
Formed in 1996 as a partnership between the State of Maryland, the City of Baltimore, the University System of Maryland and the University of Maryland Medical System, IHV is an institute of the University of Maryland School of Medicine and is home to some of the most globally-recognized and world-renowned experts in all of virology. The IHV combines the disciplines of basic research, epidemiology and clinical research in a concerted effort to speed the discovery of diagnostics and therapeutics for a wide variety of chronic and deadly viral and immune disorders – most notably, HIV the virus that causes AIDS. For more information, www.ihv.org and follow us on Twitter @IHVmaryland.
About the Global Virus Network (GVN)
The Global Virus Network (GVN) is essential and critical in the preparedness, defense and first research response to emerging, exiting and unidentified viruses that pose a clear and present threat to public health, working in close coordination with established national and international institutions. It is a coalition comprised of eminent human and animal virologists from 45 Centers of Excellence and 7 Affiliates in 29 countries worldwide, working collaboratively to train the next generation, advance knowledge about how to identify and diagnose pandemic viruses, mitigate and control how such viruses spread and make us sick, as well as develop drugs, vaccines and treatments to combat them. No single institution in the world has expertise in all viral areas other than the GVN, which brings together the finest medical virologists to leverage their individual expertise and coalesce global teams of specialists on the scientific challenges, issues and problems posed by pandemic viruses. The GVN is a non-profit 501(c)(3) organization. For more information, please visit www.gvn.org. Follow us on Twitter @GlobalVirusNews